EANM_logo

If you are an EARL accredited site in our Centers of Excellence network, and you are the sponsor/organizer of a clinical trial, and are looking for sites to join your study, you can post the details of your study on this dedicated EARL web page. Our scientific team will be reviewing the completed information only to ascertain that it is in our field. Once approved, we will post your information.  Then interested centers could reach out to you for further details. This service is free of charge for accredited centers. Please download and complete the study announcement form. Ensure that it is completed in its entirety before you submit it. 

Institution Information

German Oncology Centre , Cancer Research and Innovation Center
Department of Nuclear Medicine
1st Nikis Avenue, Ayios Athanasios, Limassol, Cyprus
Contact: Prof. Dear. Alexis Vrachimis;
email: alexis.vrachimis@goc.com.cy ; phone: +357 25 208000

Indication

Comparison of 18F-FAPI with 18F-FDG PET/CT in thyroid cancer patients with Throglobulin Elevation and Negative Iiodine Sscintigraphy (TENIS syndrome)

Study description

Some differentiated thyroid cancers (DTC) withdraw from detection and therapy with radioiodine by dedifferentiation and suffer from a poorer survival. In these situations, 131I-whole body scans typically fail to identify cancer sites. For this subset of patients FDG-PET has shown promising results. However, FDG lacks a therapeutic counterpart and cannot be utilized within the scope of theragnostics. Hence, new molecular targets such as FAPI could provide additional therapeutic approaches especially in the subset of DTC patients.

Phase

propspective/not applicable

Study design

Start date: 01Oct2021

Approximate end date: 01Oct2022

Number of subjects: 22

Number of participating institutions: 1 (sites interested to join to contact Prof. Vrachimis)

End points

  1. Changes in staging of the patient (upstaging/downstaging).
2. Possibility on modifying the therapeutic approach of the patient due to additional information that may be received from the new/under investigation radiopharmaceutical (in comparison with the standard [18F]-FDG) as a result, this could have direct impact on patients’ life expectancy.

Eligibility criteria

Inclusion criteria:
a) patients with differentiated thyroid cancer after thyroidectomy
b) patients that had received 131I therapy and have no/inadequate correltive on scintigraphy
c) increased/presistant levels of thyroglobulin
d)18 years old and older
Exclusion criteria:
a) pregnacny or lactation
b) inability to consent
c) synchronous second malignancy

Status

Recruting

Indication

Comparison of [18F]-SiF Alin-TATE and [18F]- FDOPA for Neuro-Endocrine Tumor (NET) patients

Study description

FDOPA is the only F-18 labelled radiopharmaceutical in use for imaging neuro-endocrine tumors (NETs). However, NETs can have a reduced or no expression of dopamine receptors and increased expression of somatostatin receptors (SSTs). The available PET radiopharmaceuticals that detect the SST expression are labelled with 68Ga which is a (quite costly for remote areas) 68Ge/68Ga generator product. Aim is to evaluate [18F]-SiFAlin-TATE as compared to [18F]-FDOPA in patients with neuroendocrine tumors (NET) as a novel 18F labeled SST biomarker.

Phase

propspective/not applicable

Study design

Start date: 01Oct2021

Approximate end date: 01Oct2022

Number of subjects: 20

Number of participating institutions: 1 (sites interested to join to contact Prof. Vrachimis)

End points

  1. Per lesion and per petient analysis
  2. Modification of the therapeutic approach

Eligibility criteria

Inclusion criteria:
a) diagnose/suspicionof NET
b) 18 years old and older
Exclusion criteria:
a) pregnacny or lactation
b) inability to consent
c) synchronous other malignancy

Status

Recruiting